5-Fluorouracil in PBMC BY LC-MS/MS

5-Fluorouracil in PBMC BY LC-MS/MS  (code  LC85010)  100 test package.

INSIGHTS
Fluorouracil (5-FU) is considered the most efficient and most used antineoplastic agent for the treatment of gastrointestinal, breast and ovary tumors. 5-FU acts by antagonizing thymidylate synthase (TS). Its conversion to 5 -Fluoro – 2’deossi – 5’-monophosphate (FdUMP) leads to inhibition of TS thus blocking the synthesis of DNA and interrupting the whole transcriptional process and protein synthesis. The great efficacy of this drug, however, goes hand in hand with its low therapeutic index. 5-FU is catabolized primarily by the enzyme dihydropyrimidine dehydrogenase and patients with complete or partial functional deficiency of this enzyme are likely to develop side effects such as cardiac toxicity, myelosuppression and renal failure. This method allows to determine, exvivo, the rate of degradation of the drug 5-fluorouracil (5-FU). After purification of peripheral blood lymphocytes, the cells are incubated with a known amount of 5-FU, and the amount of drug metabolised after 2 hours is determined by LC-MS/MS. The present method allows the evaluation in a preventive manner of the rate of degradation of 5 – fluorouracil, in order to highlight the toxic risk to an individual before administration of the therapy

Principle of the  Method:

This method allows to determine, ex-vivo, the rate of degradation of the drug 5-fluorouracil (5-FU). After purification of peripheral blood lymphocytes, the cells are incubated with a known amount of 5-FU, and the amount of drug metabolised after 2 hours is determined by LC-MS/MS .

	IFU
	IFU MOBILE PHASE M1
	IFU MOBILE PHASE M2